Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2005-07-05
2005-07-05
Smith, L. F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S184100, C424S190100, C514S002600, C514S012200, C435S069100
Reexamination Certificate
active
06913755
ABSTRACT:
This invention is directed to mutant SPE-A toxins or fragments thereof, vaccine and pharmaceutical compositions, and methods of using the vaccine and pharmaceutical compositions. The preferred SPE-A toxin has at least one amino acid change and is substantially non-lethal compared with the wild type SPE-A toxin. The mutant SPE-A toxins can form vaccine compositions useful to protect animals against the biological activities of wild type SPE-A toxin.
REFERENCES:
patent: 4172126 (1979-10-01), Okonogi et al.
patent: 5298396 (1994-03-01), Kotzin et al.
patent: 5336598 (1994-08-01), Kotzin et al.
patent: WO. A 85 00832 (1985-02-01), None
patent: WO 93/14634 (1993-08-01), None
patent: WO 96/40930 (1996-12-01), None
Weeks et al. (Infection and Immunity, vol. 52, No. 1, 1986, pp. 144-150).
Johnson et al. (Molecular and General Genetics vol. 203, 1986, pp. 354-356).
Bowie et al (Science, 1990, 257:1306-1310).
Burgess et al (J. of Cell Bio. 111:2129-2138, 1990).
Lazar et al. (Molecular and Cellular Biology, 1988, 8:1247-1252).
Bork (Genome Research, 2000), 10:398-400).
Mascini EM et al, J Clin Microbiol, 37 (11): 3469-74 , abstract only, 1999.
Rudinger et al “Peptide Hormone”, edited by Parson University Park Press, Jun. 1976.
Burgess et al J Cell Biol , 111:2129-2138, 1990.
Lazar et al, Mol Cell Biol 8(3): 1247, Jun. 1976.
Acharya, K. et al., “Structural Basis of Superantigen Action Inferred from Crystal Structure of Toxic—Shock Syndrome Toxin—1”, Nature 367:94-97 (1994).
Aiyar, A. et al., “Modification of the Megaprimer Method of PCR Mutagenesis: Improved Amplification of the Final Product”, BioTechniques vol. 14, No. 3 (1993) pp. 366-369.
Altschyl, S. et al., “Optimal Sequence Alignment Using Affine Gap Costs”, Bulletin of Math. Biol. 48:603-616 (1986).
Anthony—Cahill. S. et al., “Site—specific mutagenesis with unnatural amino acids”, Trends in Biochem. Sci. 14:400-403 (1989).
Barsumian et al., “Nonspecific and Specific Immunologiocal Mitogenicity by Group A Streptococcal Pyrogenic Exotoxins”, Infection and Immunity 22:681-688 (1978).
Belani, K. et al., Association of exotoxin—producing Group A streptococcal and severe disease in children, Pediatr. Infect. Dis. J. 10:351-354 (1991).
Betley et al., “Staphylcoccal Enterotoxins, Toxic Shock Syndrome Toxin and Streptococcal Pyrogenic Exotoxins: A Comparative Study of their Molecular Biology”, Chem. Immun. 55:1-35 (1992).
Birkhaug et al., “Studies in Scarlet Fever II: Studies on the Use of Convalescent Scarlet Fever Serum in Dochez Scarletino Antistreptococcic serum for the treatment of scarlet fever”, Bull. John Hopkins Hosp. 36:134-171 (1925).
Bohach et al., “Staphylcoccal and Streptococcal Pyrogenic Toxins Invovled in Toxic Shock Syndrome and Related Illnesses”, Crit. Rev. Microbiol. 17:251-272 (1989).
Bowie, J. et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions”, Science 247:1306-1310 (Mar. 16, 1990).
Braunstein, N. et al., “Sequences in Both Class II Major Histocompatibility Complex a and β Chains Contribute to the Binding of the Superantigen Toxic Shock Syndrome Toxin 1”, J. Exper. Med. 175:1301-1305 (Apr. 1, 1992).
Dohlsten et al., “Superantigen Induced Cytokines Supress Growth of Human Colon Carcinoma Cells”, Int. J. Cancer 54:482-488 (1993).
Fast, D. et al., “Toxic Shock Syndrome—Associated Staphylcoccal and Streptococcal Pyrogenic Toxins are Potent Inducers of Tumor Necrosis Factor Production”, Infection and Immunity 57:291-295 (Jan. 1989).
Goshom, S. et al., “Cloning and characterization of the gene, speC, for pyrogenic exotoxin type C from Streptococcus pyogenes”, Mol. Gen. Genet. 212:66-70 (1988).
Goshom, S. et al., “Nucelotide Sequence of Streptococcal Pyrogenic Exotoxin Type C”, Infection and Immunity 56:2518-2520 (1988).
Griggs, N. et al., “Mapping of Multiple Binding Domains of the Superantigen Staphylococcal Enterotoxin A for HLA”, J. Immunology 148:2516-2521 (Apr. 15, 1992).
Hartwig, U. et al., 1993. “Mutations affecting MHC class II binding of the superantigen streptococcal erythrogenic toxin A.” International Immunology 5 (8):869-875.
Hattori, M. et al., “Structure of the rat α2—macroglobulin—coding gene”, Gene 77:333-340 (1989).
Hauser, A. et al., “Molecular Analysis of Pyrogenic Exotoxins from Streptococcus pyogenes Isolates Associated with Toxic Shock—Like Syndrome”, J. Clin. Microbiol. 29:1562-1567 (Aug. 1991).
Hedlund et al., “Superantigen—Based Tumor Therapy in Vivo Activation of Cytotoxic T Cells”, Cancer Immun. Immunother. 36:89-93 (1993).
Hovde C.J. et al., “Investigation of the role of the disuphide bond in the activity and structure of staphylococcal enterotoxin C1”, Molecular Microbiology, 13(5):897-909 (1994).
Hsiao, Ku-chuan et al., “A Fast and simple procedure for sequencing double stranded DNA with Seqenase”, Nucleic Acids Research 19:2787 (1991).
Ihle et al., “Antibody Targeted Super Antigens Induce Lysis of Major Histocompatibility Complex Class II Negative T Cell Leukemia Lines”, Cancer Res. 55:623-628 (1995).
Iwasaki et al., “Cloning, Characterization and Overexpression of Streptococcus Pyogenes Gene Encoding a New Type of Mitogenic Factor”, FEBS Lett. 331:187-192 (1993).
Jardetzky, et al., “Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen”, Nature 368:711-718 (Apr. 21, 1994).
Jett et al., “Identification of Staphylcoccal Enerotoxin B Sequences Important for Induction of Lymphocyte Proliferation Using Synthetic Peptide Fragments of the Toxin”, Infection and Immunity 62:3408-3415 (1994).
Johnson, L. et al., “Group A streptococcal phage T12 carries the structural gene for pyrogenic exotoxin type A”, Mol. Gen. Genet. 194:52-56 (1994).
Johnson, L.P. et al, “Streptococaal pyrogenic exotoxin type A (scarlet fever toxin) is related toStaphylococcus aureusenterotoxin B”, Mol Gen Genet, 203:354-356 (May 1986).
Kappler, J. et al., “Mutations Defining Functional Regions of the Superantigen Staphylcoccal Enterotoxin B.”, J. Exp. Med. 175:387-396 (Feb. 1992).
Kline, J. et al., “Analysis of the Superantigenic Activity of Mutant and Allelic Forms of Streptococcal Pyrogenic Exotoxin A”, Infection and Immunity 64(3):861-869 (Mar. 1996).
Lee, P. et al., “Effects of Staphylococcal Toxic Shock Syndrome Toxin 1 on Aortic Endothelial Cells”, J. Infect. Dis. 164:711-9 (1991).
Lee, P. et al., “Fluid Replacement Protection of Rabbits Challenged Subcutanteously with Toxic Shock Syndrome Toxins”, Infection and Immunity 59(3):879-884 (Mar. 1991).
Marrack, P. et al., “The Staphylcoccal Enterotoxins and Their Relatives”, Science 248:705-711 (May 1990).
Martin, D., et al., Molecular Epidemiology of Group A Streptococcus M Type 1 Infections, J. Infect. Dis. 167:1112-7 (1993).
Mollick, J. et al., “Localization of a Site on Bacterial Superantigens That Determines T Cell Receptor β Chain Specificity”, J. Exp. Med. 177:283-293 (Feb. 1993).
Mollick, J. et al., “Novel Superantigen Isolated from Pathogenic Strains of Streptococcus pyogenes with Aminoterminal Homology to Staphylcoccal Enterotoxins B and C”, J. Clin. Invest. 93:710-719 (Aug. 1993).
Murray, D. et al., “Immunobiologic and Biochemical Properties of Mutants of Toxic Shock Syndrome Toxin-1”, J. Immunol (US) (1994) 152(1):87-95.
Musser et al., “Streptococcus Pyogenes Causing Toxic Shock—like Syndrome and Other Invasive Diseases: Colonal Diversity and Pyrogenic Exotoxin Expression”, Proc. Nat.'l. Acad. Sci. (USA) 88:2668-2672 (1991).
Musser, J. et al., “Infect Immun”,
Ohlendorf Douglas
Roggiani Manuela
Schlievert Patrick M.
Stoehr Jennifer Stoehr
Merchant & Gould P.C.
Regents of the University of Minnesota
Smith L. F.
Zeman Robert A.
LandOfFree
Mutants of Streptococcal toxin A and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mutants of Streptococcal toxin A and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutants of Streptococcal toxin A and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3392532